| abstract |
The present invention relates to the pharmaceutical formulation ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR) related disease or disorder, in particular cancer, more in particular is prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, chemotherapy-naive metastatic castration-resistant prostate cancer, biochemically recurrent hormone-sensitive prostate cancer, or high-risk non-metastatic Castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509 and HPMCAS. In one aspect, a solid dispersion of ARN-509 and HPMCAS is obtainable, in particular by melt-extruding a mixture comprising ARN-509 and HPMCAS and optionally subsequently grinding said melt-extruded mixture . In one aspect, a solid dispersion of ARN-509 and HPMCAS may be obtained, in particular by spray-drying a mixture comprising ARN-509 and HPMCAS dissolved in a suitable solvent. |